SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data for Capricors investigational Duchenne therapy deramiocel showed slower upper-limb decline after patients switched from placebo, prompting a sharp burst of optimism. Traders see the findings as supportive of the pending FDA review, while others question whether they resolve earlier statistical concerns; approval remains uncertain.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFIs steep, persistent share-price decline is driving discussion, with many traders frustrated by the stocks underperformance and saying there is no clear fresh catalyst. Bears point to past dilutive offerings, insider selling, elevated rates and weak buying demand, while some investors view the selloff as a buying opportunity based on the companys growth prospects.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure amid an analyst warning that AXONs growth and market-share gains may be nearing a ceiling, compounded by concern over a securities class-action lawsuit. Traders are split: bears see intensifying competition and slowing growth, while bulls cite e-commerce expansion and AXON data as evidence the business remains strong.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled speculation about a buyout or strategic investment, though traders stress that the filing does not confirm an active deal. The debate is amplified by frustration over the lack of firm satellite shipment and launch updates, alongside optimism about the companys production progress.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Positive Phase 3 melanoma cancer-vaccine results and anticipation of fuller ESMO data are driving attention, while Citis Sell downgrade over valuation has sharpened the debate between traders who see platform potential and those who view the rally as overextended.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Staggered IPO lockup expirations and insider share sales are a recurring source of selling-pressure concerns, with traders linking them to CBRSs sharp swings. Bullish traders counter that the overhang may be temporary and point to demand for Cerebrass AI-inference systems and customer deals, while bearish voices also cite valuation and broader AI-market uncertainty.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Carnivals earnings beat and raised guidance sparked a sympathy rally in NCLH and other cruise stocks. Traders are debating whether Norwegian can catch up with peers, citing high short interest and potential for a rebound while remaining cautious about fuel costs, booking yields, and management execution.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on new ASTRO biomarker data for Candels prostate-cancer therapy CAN-2409, which traders view as mechanistic support for its positive Phase 3 results and planned Q4 BLA submission. Optimism about the data and regulatory path is countered by concerns over the CEOs share sale, manufacturing work and possible BLA timing slippage.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagras quarterly results are driving attention: traders cite an adjusted earnings and operating-margin beat, while sales edged lower and fiscal guidance was reaffirmed. Reactions are mixed, with some viewing the results as a positive surprise and others focused on weak sales and continued pressure on the shares.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal Q4 earnings report is the dominant focus, with traders watching AI-driven HBM and DRAM demand, pricing, margins, and guidance for signs of how long the memory upcycle can last. The community is split between expectations for strong results and concern that high expectations are already priced in, leaving room for a sell-the-news reaction or renewed fears of a cyclical peak.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$KESPF Kleos Space Secures A$12.6 Million For Smallsat Constellation Expansion 
https://news.satnews.com/2021/09/06/kleos-space-secures-a12-6-million-for-smallsat-constellation-expansion/

Kleos Space S.A. (ASX: KSS, Frankfurt: KS1) has secured A$12.6 million (equivalent to $9.3 million) from new and existing institutional and sophisticated investors in Australia and the U.S. via a Placement of approximately 14,823,529 new CHESS Depositary Interests ( instruments traded on the Australian Stock Exchange (ASX)) over Kleos ordinary shares (CDIs) at A$0.85 (~0,63 USD) per CDI (Placement).

Satnews

Kleos Space Secures A$12.6 Million For Smallsat Constellation Expansion

StockTwits Web

Kleos Space SA

 Kleos Space Secures A$12.6 Million For Smallsat Constellation Expansion 
